Oxford Vaccine Triggers Immune Response, ‘Safe’ in Early Trials

The study showed 90 percent of people developed neutralising antibodies after one dose of the coronavirus vaccine.

In what is being seen as very promising results, University of Oxford's coronavirus vaccine has been deemed to be safe while triggering an immune response.

The long awaited phase 1 human trial results are out and have been published in The Lancet. The trial involved 1,077 people. The vaccine produced antibodies and T-cells that can fight the novel coronavirus.